These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 28724442)

  • 21. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
    van der Heijde D; Joshi A; Pangan AL; Chen N; Betts K; Mittal M; Bao Y
    Rheumatology (Oxford); 2016 Jan; 55(1):80-8. PubMed ID: 26316575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
    Levitova A; Hulejova H; Spiritovic M; Pavelka K; Senolt L; Husakova M
    Arthritis Res Ther; 2016 Nov; 18(1):275. PubMed ID: 27887637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
    Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
    J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.
    Dougados M; Wood E; Gossec L; Dubanchet A; Logeart I; van der Heijde D
    J Rheumatol; 2015 Dec; 42(12):2361-8. PubMed ID: 26568588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
    de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
    Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden.
    Gulfe A; Kapetanovic MC; Kristensen LE
    Scand J Rheumatol; 2014; 43(6):493-7. PubMed ID: 25145283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.
    Hernández-Breijo B; Plasencia-Rodríguez C; Navarro-Compán V; Martínez-Feito A; Jochems A; Kneepkens EL; Wolbink GJ; Rispens T; Diego C; Pascual-Salcedo D; Balsa A
    Arthritis Res Ther; 2019 Feb; 21(1):66. PubMed ID: 30786913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
    Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.
    Pina Vegas L; Sbidian E; Wendling D; Goupille P; Ferkal S; Le Corvoisier P; Ghaleh B; Luciani A; Claudepierre P
    Rheumatology (Oxford); 2022 Apr; 61(4):1487-1495. PubMed ID: 34270707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
    Manica SR; Sepriano A; Pimentel-Santos F; Gouveia N; Barcelos A; Branco JC; Bernardes M; Ferreira RM; Vieira-Sousa E; Barreira S; Vinagre F; Roque R; Santos H; Madeira N; Rovisco J; Daniel A; Ramiro S
    Arthritis Res Ther; 2020 Aug; 22(1):195. PubMed ID: 32825839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors.
    Hernández-Breijo B; Novella-Navarro M; Genre F; Navarro-Compán V; Martínez-Feito A; Remuzgo-Martínez S; González-Gay MÁ; Balsa A; Plasencia-Rodríguez C
    Clin Exp Rheumatol; 2023 Mar; 41(3):565-573. PubMed ID: 35579084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy.
    Lee S; Kang S; Kim H; Lee J; Kim MJ; Cha HS
    Arthritis Res Ther; 2024 Apr; 26(1):90. PubMed ID: 38664785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
    J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
    Lubrano E; Perrotta FM; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2018 Feb; 45(2):195-201. PubMed ID: 29419448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome.
    Maas F; Arends S; van der Veer E; Wink F; Efde M; Bootsma H; Brouwer E; Spoorenberg A
    J Rheumatol; 2016 Feb; 43(2):383-7. PubMed ID: 26669924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.